Hims & Hers Stock: A Divergent Path of Insider Sales and Price Recovery

Hims & Hers posts robust revenue growth and plans a major acquisition, but faces heavy insider selling and a deeply divided institutional investor base, creating a contradictory investment picture.

Shares of the telehealth company Hims & Hers gained 3.3% on April 6th, but a closer examination of its ownership reveals a more complex and contradictory situation. The institutional investor base is deeply divided, and corporate insiders have been net sellers for half a year.

Operational Strength Amidst Market Pressure

From an operational standpoint, the company continues to post robust figures. For the fiscal year 2025, revenue surged 59% to approximately $2.35 billion, with profit reaching $128 million. Looking ahead to 2026, management has set ambitious targets, forecasting revenue between $2.7 and $2.9 billion. Adjusted EBITDA is projected to land in the range of $300 to $375 million.

A key component of this growth strategy is the planned acquisition of Australian telehealth platform Eucalyptus for up to $1.15 billion. The deal structure involves an upfront cash payment of roughly $240 million at closing, with the remainder paid through guaranteed installments and performance-based components. Eucalyptus, which achieved triple-digit Annual Recurring Revenue (ARR) growth every quarter in 2025 and boasts an annualized revenue exceeding $450 million, is expected to provide access to key international markets including Australia, Japan, the United Kingdom, Germany, and Canada. The transaction is slated for completion by mid-2026.

Institutional Investors: A Battlefield of Conviction

The sentiment among major funds is sharply split. Recent quarterly filings show that 237 institutional investors increased their stakes, while 287 reduced their holdings. Notable sellers included Forerunner Ventures, which exited its position entirely by divesting nearly 9.8 million shares. Farallon Capital Management slashed its holding by 68.5%, and Renaissance Technologies cut its position by 47%. Morgan Stanley also meaningfully reduced its investment.

Despite this wave of selling, institutional investors collectively still control about 63.5% of the company's outstanding shares.

Insider Activity Sends a Clear Signal

The picture from corporate insiders is unambiguous. Over the past six months, 21 open market transactions have been recorded—every single one was a sale, with not a single purchase. Chief Financial Officer Oluyemi Okupe was particularly active, executing seven separate transactions to sell 90,485 shares for total proceeds of approximately $3.28 million.

Analyst Sentiment and Near-Term Catalysts

The stock's recovery on Monday appears to have been driven more by technical factors than fundamental shifts. Market experts point to short covering following a series of negative headlines, coupled with renewed optimism surrounding the international expansion plan. Nevertheless, the equity remains down more than 41% year-to-date, a significant drop from its 52-week high of $70.43.

The analyst consensus currently reflects a cautious stance. An average rating of "Hold" from 14 covering analysts accompanies a price target of $29.33. The company is scheduled to report its first-quarter 2026 results on May 11th, which should provide clearer evidence on whether its full-year guidance rests on a solid foundation.